Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02726789
Other study ID # REP 201
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date October 2012
Est. completion date December 2016

Study information

Verified date February 2017
Source Replicor Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The REP 201 protocol is a small exploratory study assessing the antiviral effects and tolerability of REP 2139-Ca when used with a full course of pegylated interferon (48 weeks) in treatment naive patients or in patients already receiving entecavir and continuing entecavir with treatment.


Description:

Chronic hepatitis B is a long term condition caused by infection of the body with the hepatitis B virus (HBV). This infection often results in inflammation or scarring of the liver and can eventually lead to liver cirrhosis and liver failure. These infections are also one of the major causes of the development of hepatocellular carcinoma (liver cancer).

Although some drugs have been approved to treat chronic hepatitis B infections, they do not provide a complete cure except in rare cases (a cure generally means that a person loses the hepatitis B virus from the blood and the liver and develops a durable immunological control of subsequent HBV infection). However, these drugs do significantly decrease the risk of liver damage and liver cancer arising from the presence of a chronic liver infection by slowing or stopping the production of infectious virus. Thus the primary problem associated with currently available drugs is the lack of clearance of the virus from the hepatocytes which necessitates long term treatment with these drugs. There is clearly a need to identify new drugs that can benefit patients with chronic hepatitis B infections. Nucleic acid-based polymers (NAPs) are a new class of broad-spectrum antiviral compounds which act against HBV infection by blocking the release of the surface antigen protein (HBsAg) from infected hepatocytes.

Current interim data analysis from the REP 102 assessing the activity of the NAP REP 9AC' (REP 2139, given as a calcium chelate complex [REP 2139-Ca]) in patients with chronic HBV infection indicates the following:

1. REP 2139-Ca is generally well tolerated and patients tolerate short term combined treatment (13-26 weeks) of pegylated interferon and / or thymosin alpha

2. REP 2139-Ca has achieved serum HBsAg reduction or clearance 9 of 9 patients receiving combined therapy.

3. Appearance of substantial titers of serum anti-HBs occur with the addition of immunotherapy.

4. After all treatment is withdrawn, 8 / 9 patients achieved HBV DNA < 116 copies / ml (LLOQ of the Roche Cobas platform) and sustained suppression of viremia (HBV DNA < 1000 cpm, HBsAg < 1 IU / ml) for a period of greater than 1 year was observed in four patients.

This exploratory study is designed to examine if REP 2139-Ca can be safely combined with a full course of pegylated interferon in treatment naive patients and in patients with previous and continuing therapy with entecavir and that similar antiviral effects can be observed as in the previous REP 101 and 102 protocols.


Recruitment information / eligibility

Status Completed
Enrollment 5
Est. completion date December 2016
Est. primary completion date September 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria:

- Age between 18 and 55

- HBsAg+

- Anti-HBs negative

- Patients currently receiving nucleoside based HBV polymerase inhibitors may be included in the study at the discretion of the Principle Investigator.

- HIV / hepatitis C / hepatitis delta virus negative

- Fibrosis with compensation (as determined by Fibroscan and liver enzymes)

- Non cirrhotic

- No known active cytomegalovirus infection

- Willingness to utilize adequate contraception while being treated with REP 9AC' and for 6 months following the end of treatment

- Adequate venous access allowing weekly intravenous therapies and blood tests

Exclusion Criteria:

- Evidence of cardiovascular disease

- Autoimmune hepatitis

- Presence of Wilson's disease

- Presence of severe NAFLD

- Evidence of any other co-existent liver disease

- Anti-nuclear antibody positive

- Ultrasonograph of hepato-biliary system: positive for cirrhosis of liver

- A history of ascites, hepatic encephalopathy or variceal hemorrhage

- Body weight > 100 kg

- Platelet count < 75,000, polymorphonuclear cell count < 1,500 or hematocrit < 33%

- alpha feto protein > 100 ng/ml or the presence of a hepatic mass suggestive of hepatocellular carcinoma .

- Bilirubin > 2.5 mg/dl

- Creatinine > 1.5 mg/dl

- Platelet count < 75,000 / cmm

- Serum albumin < 35 mg/ml

- Poorly controlled diabetes mellitus

- Another serious medical disorder

- A serious psychiatric disorder

- Uncontrolled hypertension

- A history of alcohol abuse within the last year

- The use of illicit drugs within the past two years

- Inability to provide informed consent

- Positive pregnancy test

- Breastfeeding

- Inability or unwillingness to provide weekly blood samples

- Poor venous access making IV infusion too difficult

Study Design


Intervention

Drug:
REP 2139-Ca
the nucleic acid polymer REP 2139 formulated as a calcium chelate complex
pegylated interferon
immunotherapy
entecavir
local generic entecavir

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Replicor Inc.

References & Publications (3)

Noordeen F, Scougall CA, Grosse A, Qiao Q, Ajilian BB, Reaiche-Miller G, Finnie J, Werner M, Broering R, Schlaak JF, Vaillant A, Jilbert AR. Therapeutic Antiviral Effect of the Nucleic Acid Polymer REP 2055 against Persistent Duck Hepatitis B Virus Infection. PLoS One. 2015 Nov 11;10(11):e0140909. doi: 10.1371/journal.pone.0140909. eCollection 2015. — View Citation

Noordeen F, Vaillant A, Jilbert AR. Nucleic acid polymers inhibit duck hepatitis B virus infection in vitro. Antimicrob Agents Chemother. 2013 Nov;57(11):5291-8. doi: 10.1128/AAC.01003-13. Epub 2013 Aug 12. — View Citation

Noordeen F, Vaillant A, Jilbert AR. Nucleic acid polymers prevent the establishment of duck hepatitis B virus infection in vivo. Antimicrob Agents Chemother. 2013 Nov;57(11):5299-306. doi: 10.1128/AAC.01005-13. Epub 2013 Aug 12. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Patients Experiencing Treatment Emergent Laboratory Test Abnormalities or Adverse Events. To record side effects, symptoms and adverse effects of exposure to REP 2139-Ca when combined pegylated interferon. 48 weeks (treatment)
Secondary Number of Patients Experiencing Reductions in Serum HBsAg To assess antiviral activity of REP 2139-Ca when combined with pegylated interferon on serum HBsAg. 48 weeks (treatment)
Secondary Number of Patients Experiencing Reductions in Serum HBV DNA To assess antiviral activity of REP 2139-Ca when combined with pegylated interferon on serum HBV DNA. 48 weeks (treatment)
Secondary Number of Patients Experiencing Serum Anti-HBs > 10 mIU / ml To assess antiviral activity of REP 2139-Ca when combined with pegylated interferon on anti-HBsAg antibody titer. 48 weeks (treatment)
See also
  Status Clinical Trial Phase
Completed NCT03272009 - Evaluation of the Safety and Pharmacology of EYP001 in HBV Subjects Phase 1
Recruiting NCT01456312 - HBsAg Related Response Guided Therapy Phase 4
Terminated NCT01886300 - An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Positive Chronic Hepatitis B in Vietnam N/A
Completed NCT01023230 - A Study to Assess DV-601 in Subjects With Chronic Hepatitis B Phase 1
Completed NCT00962975 - A Study of Pegasys Monotherapy in Patients With Chronic Hepatitis B Who Have Participated in Previous Studies Phase 1
Terminated NCT00460850 - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Lamivudine Resistant HBeAg-Negative Chronic Hepatitis B. Phase 4
Completed NCT00536263 - PegIntron Treatment of Chronic Hepatitis B e Antigen-Positive Patients (P05170/MK-4031-327) Phase 3
Completed NCT03681132 - The Norwegian Nucleoside Analogue Stop Study Phase 4
Active, not recruiting NCT05473806 - Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Type 2 Diabetes Phase 4
Withdrawn NCT01179594 - A Study of 48 Versus 96 Weeks of Peginterferon Alfa-2a [Pegasys] Treatment, With or Without Entecavir, in Patients With Chronic Hepatitis B. Phase 4
Recruiting NCT05057065 - A Clinical Research on Disease Progression and Intervention of Chronic HepatitisB
Completed NCT04439539 - A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection Phase 2
Withdrawn NCT03125213 - A Study Evaluating AL-3778 in Combination With Peginterferon Alpha-2a in Chronic Hepatitis B Subjects Phase 2
Active, not recruiting NCT04782375 - Safely Discontinue Antiviral Treatment in Patients With Chronic Hepatitis B Phase 4
Withdrawn NCT05550519 - A Study in Chronic Hepatitis B e-Antigen Negative Participants After Discontinuation of Nucleos(t)Ide Analog (NA) Treatment Early Phase 1
Completed NCT02693652 - A Study to Evaluate the Safety and Efficacy of Therapeutic Hepatitis B Vaccine Phase 1/Phase 2
Enrolling by invitation NCT04160897 - Risk of Hepatocellular Carcinoma in Patients Treated With ETV vs TDF for Chronic Hepatitis B With Compensated Cirrhosis
Active, not recruiting NCT02588937 - Active Drug Comparative Trial to Evaluate the Antiviral Activity and Safety in Chronic Hepatitis B Patients Phase 4
Completed NCT02612506 - Safety and Pharmacokinetic Study of Hepalatide(L47) in Healthy Volunteers Phase 1
Recruiting NCT02327416 - A Prospective Clinical Trial in Chronic Hepatitis B Patients NAs (Nucleotides or Nucleosides) Experienced (Anchor Study) Phase 3